Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago

NCT ID: NCT01587508

Last Updated: 2016-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the efficacy and tolerability of a new drug containing the combination meloxicam and cyclobenzaprine in the treatment of acute lumbago, compared to the same components alone.

Some eligibility criteria:

Have a normal X-ray of the lumbar spine for the age; Have a baseline score in the VAS higher than or equal to 40 mm

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lumbago

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

meloxicam - Movatec®

Group Type ACTIVE_COMPARATOR

meloxicam - Movatec®

Intervention Type DRUG

two oral tablet a day during approximately 07 days

cyclobenzaprine - Miosan®,

Group Type ACTIVE_COMPARATOR

cyclobenzaprine - Miosan®

Intervention Type DRUG

two oral tablet a day during approximately 07 days

meloxicam/cyclobenzaprine hydrochloride

Group Type EXPERIMENTAL

meloxicam/cyclobenzaprine hydrochloride

Intervention Type DRUG

two oral capsules a day during approximately 07 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

meloxicam/cyclobenzaprine hydrochloride

two oral capsules a day during approximately 07 days

Intervention Type DRUG

meloxicam - Movatec®

two oral tablet a day during approximately 07 days

Intervention Type DRUG

cyclobenzaprine - Miosan®

two oral tablet a day during approximately 07 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sign, initial and date the Informed Consent Form (ICF);
* Be between 18 and 75 years old;
* Have acute lumbago with onset in less than 72 hours;
* Have a normal X-ray;
* Have a baseline score in the VAS higher than or equal to 40 mm;

Exclusion Criteria

* Use of triptans;
* Use of monoamine oxidase inhibitors;
* Use of NSAIDs within the last week;
* Previous use of narcotics;
* Have any rheumatologic disease;
* Conditions of chronic pain;
* Have any significant chronic comorbidity;
* Previous history of gastrointestinal bleed or ulcers;
* History of allergy to any of the components of study medications;
* Recent history of a myocardial infarction, cardiac arrhythmia, cardiac conduction block or change, or congestive heart failure;
* Female patients who are pregnant or breastfeeding or who wish to become pregnant or who deny using safe contraceptive methods during the study will not be enrolled in the study;
* Have participated in another clinical trial within the last 12 months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eurofarma Laboratorios S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alceu Chueiri

Role: PRINCIPAL_INVESTIGATOR

Hospital de Base de São José do Rio Preto

Paulo Guilherme

Role: PRINCIPAL_INVESTIGATOR

Hospital Santa Marcelina

Wagner Caiafa

Role: PRINCIPAL_INVESTIGATOR

Santa Casa de Juiz de Fora

Antonio Scotton

Role: PRINCIPAL_INVESTIGATOR

Centro MIneiro de Pesquisa - Juiz de Fora

Lindomar G. Oliveira

Role: PRINCIPAL_INVESTIGATOR

Clínica de Ortopedia e Fraturas de Goiania

Antonio Carlos Ximenes

Role: PRINCIPAL_INVESTIGATOR

CIP Pesquisas Médicas Ltda

Sonia Alvarenga

Role: PRINCIPAL_INVESTIGATOR

Faculdade de Medicina ABC

Gilberto Brandão

Role: PRINCIPAL_INVESTIGATOR

Clínica Perdizes

Luciana Teixeira

Role: PRINCIPAL_INVESTIGATOR

IMA Brasil - Instituto de Medicina Avançada

Antonio Tarcísio

Role: PRINCIPAL_INVESTIGATOR

Santa Casa de Misericórdia de Belo Horizonte

Carlos Roberto Galia

Role: PRINCIPAL_INVESTIGATOR

Hospital de Clínicas de Porto Alegre

Mauro Hernandes

Role: PRINCIPAL_INVESTIGATOR

Santa Casa de Votuporanga

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CIP Pesquisas Médicas Ltda

Goiânia, Goiás, Brazil

Site Status

Clínica de Ortopedia e Fraturas de Goiânia

Goiânia, Goiás, Brazil

Site Status

Santa Casa de Misericórdia de Belo Horizonte

Belo Horizonte, Minas Gerais, Brazil

Site Status

Santa Casa de Juíz de Fora

Juiz de Fora, Minas Gerais, Brazil

Site Status

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Faculdade de Medicina ABC

Santo André, São Paulo, Brazil

Site Status

Hospítal de Base

São José Rio Preto, São Paulo, Brazil

Site Status

Clinica de Ortopedia e Fisiatria Perdizes

São Paulo, São Paulo, Brazil

Site Status

Hospital Santa Marcelina

São Paulo, São Paulo, Brazil

Site Status

IMA Brasil

São Paulo, São Paulo, Brazil

Site Status

Santa Casa de Votuporanga

Votuporanga, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EF 127

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.